Statistics
The Anavex Life Sciences Corp. stock price is currently $ 0.9335 with a total market cap valuation of $ 86.53M (92.70M shares outstanding). The Anavex Life Sciences Corp. is trading on NASDAQ under the ticker sign AVXL. Anavex Life Sciences Corp. price is up
You can buy Anavex Life Sciences Corp. (AVXL) stock on eToro. For more information check our how to buy Anavex Life Sciences Corp. (AVXL) stock guide.
Description
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Another significant drug candidate, ANAVEX 3-71, has progressed to Phase I clinical trials for frontotemporal dementia and other forms of dementia, with additional preclinical investigation underway for neurodegenerative illnesses like Alzheimer's and Parkinson's. The company's earlier-stage portfolio includes ANAVEX 1-41, a sigma-1 receptor agonist targeting depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand with potential applications in neuropathic and visceral pain; and ANAVEX 1037, aimed at treating prostate and pancreatic cancers. Anavex Life Sciences Corp. was founded in 2004 and maintains its headquarters in New York, New York.
Company Profile
- Full Name: Anavex Life Sciences Corp.
- Sector: Healthcare
- Website: https://www.anavex.com
